 Genprex Inc NASDAQ:GNPX FRA:2DE has received centralized Institutional Review Board IRB approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer NSCLC. Acclaim-1 is an open-label, multi-center Phase 12 clinical trial that combines the companys lead drug candidate, REQORSA immunogene therapy, with AstraZeneca PLCs LON:AZN NASDAQ:AZN Tagrisso osimertinib in patients with late-stage NSCLC with mutated epidermal growth factor receptors EGFRs and whose disease progressed after treatment with Tagrisso. 